K Steinbrink, F Schönlau, U Rescher, U Henseleit, T Vogel, C Sorg, C Sunderkötter
Index: Immunobiology 202(5) , 442-59, (2000)
Full Text: HTML
Myeloid-related protein (MRP) 14, an intracellular protein involved in calcium-dependent activation of myeloid cells, presents a differentiation marker for a subtype of macrophages. In experimental leishmaniasis, BALB/c mice succumb to visceral dissemination after infection with L. major, due to a Th2 cell response, while C57Bl/6 mice develop protective immunity associated with a Th1 cell response. We have previously shown that resistance in (C57Bl/6 mice was also associated with a significantly lower percentage of MRP14-positive cells in the infiltrate than in susceptible BALB/c mice. In C57Bl/6 mice, weekly injections of bone marrow (BM) cells enriched with MRP14-positive cells (d1 of culture) did not reverse, but prolonged the course of infection, associated with increased local parasite spread. In BALB/c mice a single dose of an antiphlogistic agent (dexamethasone or lipoxygenase inhibitor) was associated with reduction of infiltrating MRP14-positive cells and also with a decrease of parasite loads in footpads, lymph nodes as well as spleens, and with delayed progression of disease, Double labeling experiments in vitro revealed that at least 43.1% of MRP14-positive mononuclear cells in BM cultures (8h) had phagocytosed parasites after 4 h of co-incubation. Activation by IFN-gamma (20 U/ml) for 24h and 48h did not significantly reduce parasite load in these cells. In contrast, 77.0% of F4/80-positive macrophages (6d of culture) were infected with L. major parasites and these cells responded to activation with IFN-gamma (20 U/ml) with significant reduction of parasite load (25.3%). The protein MRP14 did not have an effect on parasite survival in vitro. Thus, the impaired capability of MRP14-positive cells to kill L. major upon stimulation may be one reason for the adverse course of infection observed with their increased appearance.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
BAY-X 1005
CAS:128253-31-6 |
C23H23NO3 |
|
Leukotriene modifiers in the treatment of asthma. Look promi...
1998-04-25 [BMJ 316(7140) , 1257-8, (1998)] |
|
BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double ...
2007-09-01 [J. Physiol. Pharmacol. 58(3) , 583-8, (2007)] |
|
Inhibition of 5-LO activating protein (FLAP) activity decrea...
2002-01-01 [Adv. Exp. Med. Biol. 507 , 79-83, (2002)] |
|
Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and...
1999-09-09 [J. Vet. Pharmacol. Ther. 20(4) , 296-307, (1997)] |
|
Potential anti-inflammatory effects of 5-lipoxygenase inhibi...
1997-12-01 [J. Physiol. Pharmacol. 48(4) , 529-36, (1997)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
